Compare Incyte Corporation (INCY) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Wix.Com Ltd — how do they compare? Incyte Corporation trades at $113.13 (market cap $22.85B), while Wix.Com Ltd trades at $75.09 (market cap $3.11B). The key difference: Incyte Corporation is far larger — about 7.3× Wix.Com Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Wix.Com Ltd for 62 Days on average.
| INCY | WIX | |
|---|---|---|
Market Cap | $22.85B | $3.11B |
Volume | 1,927,029 | 809,286 |
Sector | Health | Technology |
52-Week High | $129.93 | $145.54 |
52-Week Low | $83.80 | $40.43 |
Typical Hold Time | 33 Days | 62 Days |
Enterprise Value | $18.35B | $4.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
WIX trades at $75.06, up 2.86% today, near the consensus price target of $77.00. The stock shows mixed technical signals with a neutral overall rating but bullish moving averages. Revenue growth is strong, reaching $1.99 billion in 2025, though net income turned positive only recently. However, negative shareholder equity and a class action lawsuit filed in September 2026 present significant headwinds. Analyst sentiment remains largely positive with 63% buy ratings, but recent earnings misses add caution.
The outlook is cautiously optimistic given solid revenue expansion and analyst support, but high valuation multiples, litigation overhang, and inconsistent profitability pose risks. Investors should weigh growth potential against financial stability concerns and legal uncertainties before committing capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
